摘要
目的:探讨循环腹腔热灌注化疗(CHPPC)联合静脉化疗对老年胃癌患者术后肿瘤标志物含量及机体免疫功能的影响。方法:将104例胃癌患者按数字表法随机纳入对照组(行单纯静脉化疗)和研究组(行CHPPC联合静脉化疗)各52例,比较两组患者短期化疗效果、肿瘤标志物表达量、免疫功能、药物毒副作用、复发率及生存率的差异。结果:研究组与对照组短期治疗有效率(67.3%vs 28.8%)及肿瘤标志物CEA(3.42±2.44 vs 9.64±4.53)、CA199(15.44±4.35 vs 29.52±9.53)、CA242(4.31±2.52 vs 18.7±7.45)差异均具有统计学意义(P<0.05);且两组CD3^+、CD4^+、CD8^+及CD4^+/CD8^+值差异也有统计学意义(P<0.05);此外研究组复发率(19.2%)低于对照组(48.0%)(P<0.05)。结论:采用CHPPC联合静脉化疗治疗老年胃癌患者,有助于提高患者短期治疗效果,并降低患者肿瘤标志物表达水平,提高免疫功能。
Objective：To evaluate the clinical effect of continuous hyperthermic peritoneal perfusion chemotherapy（CHPPC） combined with intravenous chemotherapy on tumor marker contents and immune function in elderly patients with gastric cancer.Methods： One hundred and four patients with gastric cancer were randomly divided into control group with intravenous chemotherapy only（n=52） and study group with CHPPC combined with intravenous chemotherapy（n=52） according to the digital table.The difference of short-term chemotherapeutic effect, tumor marker expression levels, immune function, medication side effects, recurrence and survival rate were compared between the two groups.Results： There was a statistically significant difference between the two groups in short-term therapeutic response rate（67.3% vs 28.8%）, tumor markers CEA（3.42±2.44 vs 9.64±4.53）, CA199（15.44±4.35 vs 29.52±9.53） and CA242（4.31±2.52 vs 18.7±7.45）（P＆lt;0.05）.In addition, statistically significant differences were found in the levels of CD3＋, CD4＋, CD8＋ and CD4＋/CD8＋ between the two groups（P＆lt;0.05）.The recurrence rate in the study group（19.2%） was significantly lower than that in the control group（48.0%）（P＆lt;0.05）.Conclusion： CHPPC combined with intravenous chemotherapy in the treatment of elderly patients with gastric cancer can improve the short-term therapeutic effect and immune function, and reduce the expression levels of tumor markers.
出处
《东南大学学报（医学版）》
CAS
北大核心
2017年第3期439-443,共5页
Journal of Southeast University(Medical Science Edition)
关键词
循环腹腔热灌注化疗
胃癌
免疫功能
肿瘤标志物
continuous hyperthermic peritoneal perfusion chemotherapy
gastric cancer
immune function
tumor markers
